Modeling the Impact of Routine Treatment on Schistosomiasis Elimination in Kenya

Joy Kalekye Nthiwa





Schistosomiasis in Kenya


Schistosomiasis is a neglected tropical disease caused by parasitic worms of genus Schistosoma.

1 Prevalence

Over 6 million people are at risk, with ~2.5 million infected

- 2 Impact
 - Chronic illness, reduced productivity, and increased healthcare costs
- Transmission
 Individual contact with cercariae-infected freshwater bodies
- **4** Elimination Goals

Elimination as a public health problem (WHO) and Kenya's BTS





Current Control Strategies

WHO preventive chemotherapy guidelines:

Mass drug administration (MDA) targeting at least 75% (2+ years):

- Once a year treatment in areas with prevalence ≥10%
- Twice a year treatment in areas with prevalence ≥50%

Kenya preventive chemotherapy guidelines:

Annual MDA campaign for areas with prevalence ≥2% targeting 2+ years at 75% coverage



Challenges to Elimination

Achieving sustained therapeutic coverage remains a challenge:

Never Treated

Individuals who have never received treatment after multiple MDA rounds.

Not Treated

Individuals who were not treated during the previous campaign due to factors such as age.

Impact

Effect of maintenance of the targeted therapeutic coverage beyond campaign period, on the elimination targets.

Proposed Intervention

Introduction of routine house-to-house treatment following MDA campaign.

Goal

Maintain targeted therapeutic coverage beyond campaign period

Approach

MDA campaigns followed by routine house-to-house treatment.

Benefit

Reduce infection reservoir, accelerate elimination timeline.



Research Question and Objectives

Research Question

How does the implementation of routine house-to-house treatment following MDA campaign affect the prevalence of schistosomiasis and the timeline for achieving elimination in Kenya by 2030?

Specific Objectives

• Model the transmission dynamics of schistosomiasis in Kenya.

• Evaluate the impact of routine house-to-house treatment on the timeline for reaching elimination targets.


Literature Review

1 Importance of Treatment Coverage:


- Minimizing the proportion of NT individuals can shorten the duration of control programs (Kura et al., 2024).
- Focusing treatment on a limited age group while excluding other high-risk groups can result in undetected disease rebound and irreversible morbidity (Kate et al., 2014, Faust et al., 2020).

2 Role of Agent-Based Models:

By simulating the complex interactions between individuals, their behavior, and the environment, ABMs can shed light on disease dynamics and guide optimal control strategies (Graham et al., 2021).



Model Structure




Model Assumptions

- Homogenous mixing of susceptible, exposed, infected population
- Individuals are classified into susceptible, exposed, infected and recovered population
- Treatment is administered to the susceptible, exposed and infectious population

4 Not all individuals adhere to treatment

Preventive chemotherapy does not prevent re-infection





Scenario Modeling: Exploring Intervention Options

Scenario	MDA Coverage	Routine Treatment
Baseline	75%	None
Intervention 1	75%	Yes
Intervention 2	80%	Yes
Intervention 3	85%	Yes

Model Implementation


 Define agent, environment, attributes and interactions, decision rules

• Set up the different classes

• Implement simulation loop

• Data collection and analysis

Results visualization





References

Cliff Kerr, Robyn Stuart, Romesh Abeysuriya, Jamie Cohen, Paula Sanz-Leon, Alina Muellenmeister, Daniel Klein (2024). Starsim: A fast, flexible toolbox for agent-based modeling of health and disease. In preparation

Colley, Daniel G., Amaya L. Bustinduy, W. Evan Secor, and Charles H. King. 2014. "Human Schistosomi- asis." The Lancet 383 (9936): 2253-64. https://doi.org/10.1016/S0140-6736(13)61949-2.

Faust CL, Osakunor DNM, Downs JA, Kayuni S, Stothard JR, Lamberton PHL, Reinhard-Rupp J, Rollinson D. Schistosomiasis Control: Leave No Age Group Behind. Trends Parasitol. 2020 Jul;36(7):582-591. doi: 10.1016/j.pt.2020.04.012. Epub 2020 May 16. PMID: 32430274; PMCID: PMC7905337.

Gichuki, Paul M., Stella Kepha, Damaris Mulewa, Janet Masaku, Celestine Kwoba, Gabriel Mbugua, Humphrey D. Mazigo, and Charles Mwandawiro. 2019. "Association Between Schistosoma Mansoni Infection and Access to Improved Water and Sanitation Facilities in Mwea, Kirinyaga County, Kenya." *BMC Infectious Diseases* 19 (1): 503. https://doi.org/10.1186/s12879-019-4105-1.

Kepha S, Ochol D, Wakesho F, Omondi W, Njenga SM, Njaanake K, Kihara J, Mwatha S, Kanyi C, Oloo JO, Kibati P, Yard E, Appleby LJ, McRae-McKee K, Odiere MR, Matendechero SH. Precision mapping of schistosomiasis and soil-transmitted helminthiasis among school age children at the coastal region, Kenya. PLoS Negl Trop Dis. 2023 Jan 5;17(1):e0011043. doi: 10.1371/journal.pntd.0011043. PMID: 36602986; PMCID: PMC9847902.

Kura, Klodeta, Nyamai Mutono, Maria-Gloria Basáñez, Luc E. Coffeng, S. M. Thumbi, and Roy M. An-derson. n.d. "How Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma Mansoni Elimination as a Public Health Problem by 2030?" https://doi.org/10.1101/2023.10.20.23297322.

Ministry of Health. 2022. "Kenya National Master Plan for the Elimination of Neglected Tropical Diseases, 2023 - 2027." Nairobi.

Mitchell KM, Mutapi F, Mduluza T, Midzi N, Savill NJ, Woolhouse ME. Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium. PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3059. doi: 10.1371/journal.pntd.0003059. PMID: 25079601; PMCID: PMC4117464.

World Health Organization. 2022. "Ending the Neglect to Attain the Sustainable Development Goals A Rationale for Continued Investment in Tackling Neglected Tropical Diseases 2021–2030." Geneva.